Table of Contents
A 2025 focus article published in the Journal of Pain proposes that psilocybin could act as a “psychophysical adaptogen” in chronic pain rehabilitation, potentially loosening what the authors call self-pain enmeshment and reducing psychological barriers to exercise engagement. This is a theoretical framework, not a clinical trial.
- Identity and pain are intertwined. The authors describe “self-pain enmeshment,” a state in which a person’s sense of self becomes fused with their pain experience, reinforcing fear of movement and avoidance behavior that worsens functional outcomes.
- Psilocybin may shift brain network dynamics. The article proposes that psilocybin’s known effects on the Default Mode Network, Salience Network, and Frontoparietal Network could loosen rigid cognitive patterns that keep pain patients locked in maladaptive cycles.
- The “afterglow” period is highlighted as a rehabilitation window. The authors suggest that the days to weeks following a psilocybin session, a period often marked by improved mood and openness, could be strategically used to introduce structured movement therapy.
- This is a conceptual framework, not a tested protocol. The paper does not report clinical trial data; it proposes an integrative model and calls for future research to test whether embedding movement therapy into psilocybin study protocols improves functional outcomes.
- Model
- human (conceptual framework, no experimental participants)
- Sample
- No participants; focus article synthesizing existing literature
- Dose
- Not tested; psilocybin dosing discussed in general terms from existing research
- Design
- Perspective and focus article proposing a novel integrative framework
- Key outcome
- A theoretical model proposing that psilocybin’s effects on self-perception and brain connectivity could enhance engagement with chronic pain rehabilitation
- Main limitation
- No original data collected; all proposed mechanisms await empirical testing in human trials
What the Research Examined
This entry is based on a focus article by Cherup et al. published in the Journal of Pain in September 2025. Rather than reporting results from a clinical trial, it synthesizes existing findings and proposes a novel theoretical framework for how psilocybin might be embedded into structured chronic pain rehabilitation programs. No participants were enrolled and no experimental data were collected for this paper.
The authors center their argument on a concept they call self-pain enmeshment, in which a person’s pain schema, disability schema, and self-schema overlap so extensively that identity becomes inseparable from the pain experience. This psychological fusion, they argue, drives maladaptive states including pain catastrophizing, kinesiophobia (fear of movement), and depression, all of which cause patients to disengage from physical rehabilitation. The article draws on prior work in psychedelic-assisted therapy for psychiatric disorders and on neuroscience research showing that psilocybin alters functional connectivity among the Default Mode Network, Salience Network, and Frontoparietal Network, regions centrally involved in self-referential processing and sensorimotor integration.
The framework’s practical core is a proposed timeline: psilocybin sessions would be followed by targeted movement therapy sessions timed to coincide with the post-acute “afterglow” period, when mood, openness to experience, and social connectedness are often elevated. The authors suggest this window could be used to introduce exercise engagement and to reinforce positive identity shifts before rigid cognitive patterns reassert themselves. For readers curious about how altered brain states might underpin healing, the broader context of psilocybin’s effects on neural connectivity and consciousness helps situate why the authors see this particular sacrament as a plausible lever for rehabilitation science.
What the Findings Show
- Self-pain enmeshment model.The authors describe three overlapping schemas, pain, disability, and self, whose degree of overlap determines the severity of distress and avoidance. Greater overlap is associated with stronger maladaptive cognitive-affective states including fear avoidance and pain catastrophizing.
- Proposed neural mechanism.Psilocybin is proposed to disrupt rigid top-down processing mediated by the Default Mode Network, Salience Network, and Frontoparietal Network, enabling a reorganization of self-referential priors that currently prohibit exercise engagement.
- Afterglow rehabilitation window.The article identifies the days to weeks following psilocybin administration, commonly characterized by improved mood, reduced anxiety, and increased social connectedness, as a strategically important period to deploy structured movement therapy.
- Acute psilocybin timeline (from reviewed literature).The authors note, drawing on existing research, that acute perceptual effects typically begin within 30 to 60 minutes of administration and may last 4 to 8 hours, with post-acute psychological changes extending well beyond that window.
Because this is a perspective and focus article rather than a clinical study, none of these observations are reported as measured outcomes from new data. They represent the authors’ synthesis of prior literature and their proposed framework. The value of the paper lies in articulating a testable hypothesis and calling for future trial designs that embed physical rehabilitation into psilocybin-assisted therapy protocols, a methodological step that has been largely absent from existing research.
Could psilocybin help chronic pain patients engage in physical rehabilitation?
A 2025 theoretical framework published in the Journal of Pain argues it might, by disrupting the psychological fusion between a person’s identity and their pain, potentially reducing fear of movement and improving openness to exercise during the post-session recovery window. Clinical trials are needed to test this idea.
What This Is, and What It Is Not
This is This is a focus and perspective article, a theoretical framework that synthesizes existing literature and proposes a novel rehabilitation model; it does not present original experimental or clinical data.
This is not This is not a clinical trial, a meta-analysis, or a study that measured outcomes in human participants. Nothing here establishes that psilocybin treats or cures chronic pain, and no safe or effective dose for this application has been identified. This content is educational and is not medical advice.
Our Take
For our community, the language Cherup and colleagues reach for, reframing, meaning-making, loosening of entrenched identity, is language that will feel familiar. Those of us who have sat with psilocybin as a sacrament know how thoroughly a session can shift the story we tell about ourselves. What the authors are trying to formalize scientifically is something many in this community have witnessed: that the self is more porous than chronic suffering makes it feel, and that there may be a window, right after the experience, when a person is genuinely open to becoming someone who moves, who stretches, who returns to the body with curiosity rather than dread. The science has not caught up to that observation yet, and the authors are right to say so plainly. But the hypothesis itself feels true to what psilocybin, approached with reverence and intention, can do.
If you or someone you love lives inside the exhausting loop of pain, avoidance, and diminished identity, this kind of research matters, not because it offers a solution today, but because it names the problem honestly. Chronic pain is not just a physical event; it is a story the self gets locked inside. Whether you are in an early Grounding phase, learning to trust the body again, or somewhere deeper in Integration, working to weave insight back into daily life, the idea that psilocybin might help widen those possibilities is worth holding with care. We invite you to explore what emerging science, and your own discernment, have to offer.
Frequently Asked Questions
What is self-pain enmeshment?
Self-pain enmeshment is a concept describing how a person’s sense of identity can become so fused with their chronic pain experience that pain defines who they are. The authors argue this fusion drives fear of movement, depression, and disengagement from rehabilitation.
Is psilocybin being used to treat chronic pain right now?
Not in standard clinical practice. Research is in early stages. This 2025 paper is a theoretical framework, not a clinical trial. A small number of early studies and case reports have examined the topic, but no approved therapeutic protocol for pain currently exists.
What is the afterglow period the article describes?
The afterglow refers to the days to weeks following a psilocybin session when participants often report elevated mood, reduced anxiety, and greater social connectedness. The authors propose this window as an opportunity to introduce physical rehabilitation exercises.
How does psilocybin affect the brain in the context of chronic pain?
The authors propose that psilocybin alters activity and connectivity in the Default Mode Network, Salience Network, and Frontoparietal Network, regions involved in self-referential thought and sensory processing. This could loosen rigid thought patterns that reinforce pain-related identity and avoidance.
Does this paper prove psilocybin works for chronic pain?
No. This is a perspective article proposing a framework for future research. It does not report clinical trial data or measured outcomes. The authors explicitly call for empirical studies to test whether integrating movement therapy into psilocybin protocols improves functional outcomes.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
